Abstract
Adding docetaxel or androgen receptor signalling inhibitor (ARSI) at start of androgen deprivation therapy (ADT) for mPCa improves progression-free survival (PFS) and overall survival (OS). Duration of benefit is variable; although serum PSA at 7 months (mth) associates with differential outcome, physicians still lack the tools to identify who will develop early resistance and require alternative or intensified treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have